LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Longwe, Herbert; Gordon, Stephen; Malamba, Rose; French, Neil (2010)
Publisher: BioMed Central
Journal: BMC Infectious Diseases
Languages: English
Types: Article
Subjects: qw_700, Research Article, RC109-216, Infectious Diseases, Infectious and parasitic diseases, wc_503_5, wc_503, qv_268.5

Abstract

Background

Untreated human immunodeficiency virus (HIV) disease disrupts B cell populations causing reduced memory and reduced naïve resting B cells leading to increases in specific co-infections and impaired responses to vaccines. To what extent antiretroviral treatment reverses these changes in an African population is uncertain.

Methods

A cross-sectional study was performed. We recruited HIV-uninfected and HIV-infected Malawian adults both on and off antiretroviral therapy attending the Queen Elizabeth Central hospital in Malawi. Using flow cytometry, we enumerated B cells and characterized memory B cells and compared these measurements by the different recruitment groups.

Results

Overall 64 participants were recruited - 20 HIV uninfected (HIV-), 30 HIV infected ART naïve (HIV+N) and 14 HIV-infected ART treated (HIV+T). ART treatment had been taken for a median of 33 months (Range 12-60 months). Compared to HIV- the HIV+N adults had low absolute number of naïve resting B cells (111 vs. 180 cells/μl p = 0.008); reduced memory B cells (27 vs. 51 cells/μl p = 0.0008). The HIV+T adults had B-cell numbers similar to HIV- except for memory B cells that remained significantly lower (30 vs. 51 cells/μl p = 0.02). In the HIV+N group we did not find an association between CD4 count and B cell numbers.

Conclusions

HIV infected Malawian adults have abnormal B-cell numbers. Individuals treated with ART show a return to normal in B-cell numbers but a persistent deficit in the memory subset is noted. This has important implications for long term susceptibility to co-infections and should be evaluated further in a larger cohort study.

  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. French N, Moore M, Haikala R, Kayhty H, Gilks CF: A case-control study to investigate serological correlates of clinical failure of 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults. J Infect Dis 2004, 190(4):707-712.
    • 2. Klugman KP, Madhi SA, Feldman C: HIV and pneumococcal disease. Curr Opin Infect Dis 2007, 20(1):11-15.
    • 3. French N, Gilks C: Pneumococcal Disease. In Manson's Tropical Diseases. Edited by: Cook GC, Zumla AI. Elsevier; , 21 2003:.
    • 4. Richard Y, Lefevre E, Krzysiek R: B cells in the line of sight of HIV-1. In Cellular Aspects of HIV Infection. Edited by: Cossarizza A, Kaplan D. New York: Wiley InterScience; 2002:69-102.
    • 5. Townsley-Fuchs J, Neshat MS, Margolin DH, Braun J, Goodglick L: HIV-1 gp120: a novel viral B cell superantigen. Int Rev Immunol 1997, 14(4):325-338.
    • 6. Dawood MR, Conway B, Patenaude P, Janmohamed F, Montaner JS, O'Shaughnessy MV, Hammond GW: Association of phenotypic changes in B cell lymphocytes and plasma viral load in human immunodeficiency virus-infected patients. J Clin Immunol 1998, 18(3):235-240.
    • 7. De Milito A, Morch C, Sonnerborg A, Chiodi F: Loss of memory (CD27) B lymphocytes in HIV-1 infection. Aids 2001, 15(8):957-964.
    • 8. Jacobsen MC, Thiebaut R, Fisher C, Sefe D, Clapson M, Klein N, Baxendale HE: Pediatric human immunodeficiency virus infection and circulating IgD+ memory B cells. J Infect Dis 2008, 198(4):481-485.
    • 9. Chong Y, Ikematsu H, Yamamoto M, Murata M, Yamaji K, Nishimura M, Nabeshima S, Kashiwagi S, Hayashi J: Increased frequency of CD27- (naive) B cells and their phenotypic alteration in HIV type 1-infected patients. AIDS Res Hum Retroviruses 2004, 20(6):621-629.
    • 10. Deterre P, Berthelier V, Bauvois B, Dalloul A, Schuber F, Lund F: CD38 in Tand B-cell functions. Chem Immunol 2000, 75:146-168.
    • 11. Moir S, Fauci AS: Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease. J Allergy Clin Immunol 2008, 122(1):12-19, quiz 20-11.
    • 12. Moir S, Fauci AS: B cells in HIV infection and disease. Nat Rev Immunol 2009, 9(4):235-245.
    • 13. Fournier AM, Baillat V, Alix-Panabieres C, Fondere JM, Merle C, Segondy M, Huguet MF, Reynes J, Vendrell JP: Dynamics of spontaneous HIV-1 specific and non-specific B-cell responses in patients receiving antiretroviral therapy. Aids 2002, 16(13):1755-1760.
    • 14. Moir S, Malaspina A, Ho J, Wang W, Dipoto AC, O'Shea MA, Roby G, Mican JM, Kottilil S, Chun TW, et al: Normalization of B cell counts and subpopulations after antiretroviral therapy in chronic HIV disease. J Infect Dis 2008, 197(4):572-579.
    • 15. Nilssen DE, Oktedalen O, Brandtzaeg P: Intestinal B cell hyperactivity in AIDS is controlled by highly active antiretroviral therapy. Gut 2004, 53(4):487-493.
    • 16. Notermans DW, de Jong JJ, Goudsmit J, Bakker M, Roos MT, Nijholt L, Cremers J, Hellings JA, Danner SA, de Ronde A: Potent antiretroviral therapy initiates normalization of hypergammaglobulinemia and a decline in HIV type 1-specific antibody responses. AIDS Res Hum Retroviruses 2001, 17(11):1003-1008.
    • 17. Beniguel L, Begaud E, Cognasse F, Gabrie P, Mbolidi CD, Sabido O, Marovich MA, DeFontaine C, Fresard A, Lucht F, et al: Identification of germinal center B cells in blood from HIV-infected drug-naive individuals in Central Africa. Clin Dev Immunol 2004, 11(1):23-27.
    • 18. Berberian L, Goodglick L, Kipps TJ, Braun J: Immunoglobulin VH3 gene products: natural ligands for HIV gp120. Science 1993, 261(5128):1588-1591.
    • 19. Agematsu K, Hokibara S, Nagumo H, Komiyama A: CD27: a memory B-cell marker. Immunol Today 2000, 21(5):204-206.
    • 20. D'Orsogna LJ, Krueger RG, McKinnon EJ, French MA: Circulating memory Bcell subpopulations are affected differently by HIV infection and antiretroviral therapy. Aids 2007, 21(13):1747-1752.
    • 21. Barry PM, Zetola N, Keruly JC, Moore RD, Gebo KA, Lucas GM: Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990-2003. Aids 2006, 20(3):437-444.
  • No related research data.
  • No similar publications.

Share - Bookmark

Funded by projects

  • WT

Cite this article